Dr Sudpreeda Chainitikun
Specialty
- Internal medicine
Sub Specialty
- Oncology
Routine Schedule
- Monday: 08.00-17.00
- Tuesday: 08.00-17.00
- Wednesday: 08.00-17.00
- Friday: 08.00-17.00
- Saturday: 08.00-13.00
Location
3rd Floor, Counter A (WEST Lift)
Treatments And Services
- • Diagnosis, Planning and Systematic Therapy for Solid Cancer
- • Chemotherapy
- • Targeted Therapy
- • Immunotherapy
- • Palliative Care Service
Educations
Clinical Research Postdoctoral Fellow
University of Texas MD Anderson Cancer Center, USA
Master of Science in Health Development
Faculty of Medicine, Chulalongkorn University, Thailand
2015
Doctor of Medicine
Faculty of Medicine, Srinakarinwirot University, Thailand
2009
Certifications
Research And Publications
Chainitikun, S., Long, J. P., Rodriguez-Bautista, R., Iwase, T., Tripathy, D., Fujii, T., & Ueno, N. T. (2020). The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer. Breast Cancer Research and Treatment, 1-11.1.
Chainitikun, S., Saleem, S., Lim, B., Valero, V., & Ueno, N. T.(2020). Update on Systemic Treatment for Newly Diagnosed Inflammatory Breast Cancer. Journal of Advanced Research 2020. https://doi.org/10.1053/j.sult.2020.08.016
Wang, X.; Semba, T.; Phi, L.T.H.; Chainitikun, S.; Iwase, T.; Lim, B.; Ueno, N.T. Targeting Signaling Pathways in Inflammatory Breast Cancer. Cancers 2020, 12, 2479.
Colleen M. Costelloe, Patrick P. Lin, Hubert H. Chuang, Behrang Amini, Sudpreeda Chainitikun, Tse-Kuan Yu, Naoto T. Ueno, William A. Murphy, John E. Madewell, Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy, Seminars in Ultrasound, CT and MRI, 2020, https://doi.org/10.1053/j.sult.2020.08.016.
Kida K, Hess KR, Lim B, Iwase T, Chainitikun S, Valero V, Lucci A, Le-Petross HC, Woodward WA, Krishnamurthy S, Hortobagyi GN, Tripathy D, Ueno NT. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers (Basel). 2020 Oct 24;12(11):3105. doi: 10.3390/cancers12113105. PMID: 33114311; PMCID: PMC7690918.